Barnard J, Newman L S
National Jewish Medical and Research Center, Denver, Colorado 80206, USA.
Curr Opin Rheumatol. 2001 Jan;13(1):84-91. doi: 10.1097/00002281-200101000-00014.
Sarcoidosis is a systemic granulomatous disorder of unknown cause. It has protean manifestations and can affect any organ, including bones, joints, muscles, and vessels. This article reviews the most recent information on the immunologic and inflammatory pathogenesis of sarcoidosis and its implications for therapy. Sarcoidosis results from an overexuberant T cell-mediated immune response to the unknown antigen. This antigen presentation/T cell antigen recognition event occurs in a microenvironment that is suffused in proinflammatory cytokines and growth factors that promote cell attraction, adhesion, permeability changes, further cytokine production, and release. An amplified cellular immune response ensues, leading to granuloma formation and fibrosis. The article summarizes the new developments in the medical literature related to the rheumatologic manifestations and their detection and management in sarcoidosis patients. Osseous involvement in sarcoidosis is often underdiagnosed because it can be asymptomatic. New imaging techniques improve detection. Management of osteoporosis in sarcoidosis patients requires special attention because these patients often have an underlying disorder in calcium metabolism that results in hypercalcuria and hypercalcemia. Joint manifestations, such as the classic Lofgren syndrome with accompanying erythema nodosum, may be self-limited or may become chronic, presenting an ongoing therapeutic challenge. Sarcoidosis vasculitis can be devastating, affecting virtually any vessel in any organ and causing significant morbidity. Muscle involvement, like the bony involvement, is underdiagnosed. Symptoms of muscle weakness, aches, tenderness, and fatigue should prompt consideration of occult sarcoid myositis, often with accompanying neurogenic atrophy. Sarcoidosis treatment usually starts with a period of observation before pharmacologic intervention. Corticosteroids remain the first-line therapy. Alternatives to corticosteroids are often introduced either because of steroid intolerance or in an attempt to reduce steroid dose and side effects. The advantages and disadvantages of these second line therapies are reviewed. Medical vigilance, with attention to new patient symptoms, is important in the management of sarcoidosis, because of the tendency of this disease to present in so many and diverse patterns.
结节病是一种病因不明的全身性肉芽肿性疾病。它有多种表现形式,可累及任何器官,包括骨骼、关节、肌肉和血管。本文综述了结节病免疫和炎症发病机制的最新信息及其对治疗的意义。结节病是由对未知抗原的过度活跃的T细胞介导的免疫反应引起的。这种抗原呈递/T细胞抗原识别事件发生在一个充满促炎细胞因子和生长因子的微环境中,这些因子促进细胞吸引、黏附、通透性改变、进一步的细胞因子产生和释放。随后会出现放大的细胞免疫反应,导致肉芽肿形成和纤维化。本文总结了医学文献中与结节病患者的风湿性表现及其检测和管理相关的新进展。结节病的骨受累往往诊断不足,因为它可能无症状。新的成像技术提高了检测率。结节病患者骨质疏松症的管理需要特别关注,因为这些患者通常存在钙代谢的潜在紊乱,导致高钙尿症和高钙血症。关节表现,如伴有结节性红斑的经典 Löfgren 综合征,可能是自限性的,也可能会变成慢性,带来持续的治疗挑战。结节病血管炎可能具有破坏性,几乎可影响任何器官的任何血管,并导致严重的发病率。肌肉受累与骨受累一样,诊断不足。肌肉无力、疼痛、压痛和疲劳症状应促使考虑隐匿性结节病性肌炎,通常伴有神经源性萎缩。结节病治疗通常在药物干预前先进行一段时间的观察。皮质类固醇仍然是一线治疗药物。由于类固醇不耐受或为了减少类固醇剂量和副作用,通常会引入皮质类固醇的替代药物。本文综述了这些二线治疗方法的优缺点。由于这种疾病有多种多样的表现形式,在结节病的管理中,密切关注新出现的患者症状进行医学监测很重要。